Rain Therapeutics Stock Debt To Equity
| RAINDelisted Stock | USD 1.41 0.01 0.70% |
Rain Therapeutics fundamentals help investors to digest information that contributes to Rain Therapeutics' financial success or failures. It also enables traders to predict the movement of Rain Stock. The fundamental analysis module provides a way to measure Rain Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Rain Therapeutics stock.
Rain |
Rain Therapeutics Company Debt To Equity Analysis
Rain Therapeutics' Debt to Equity is calculated by dividing the Total Debt of a company by its Equity. If the debt exceeds equity of a company, then the creditors have more stakes in a firm than the stockholders. In other words, Debt to Equity ratio provides analysts with insights about composition of both equity and debt, and its influence on the valuation of the company.
Current Rain Therapeutics Debt To Equity | 0 % |
Most of Rain Therapeutics' fundamental indicators, such as Debt To Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Rain Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
High Debt to Equity ratio typically indicates that a firm has been borrowing aggressively to finance its growth and as a result may experience a burden of additional interest expense. This may reduce earnings or future growth. On the other hand a small D/E ratio may indicate that a company is not taking enough advantage from financial leverage. Debt to Equity ratio measures how the company is leveraging borrowing against the capital invested by the owners.
CompetitionAccording to the company disclosure, Rain Therapeutics has a Debt To Equity of 0.003%. This is 99.99% lower than that of the Biotechnology sector and 99.98% lower than that of the Health Care industry. The debt to equity for all United States stocks is 99.99% higher than that of the company.
Rain Debt To Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Rain Therapeutics' direct or indirect competition against its Debt To Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Rain Therapeutics could also be used in its relative valuation, which is a method of valuing Rain Therapeutics by comparing valuation metrics of similar companies.Rain Therapeutics is currently under evaluation in debt to equity category among its peers.
Rain Fundamentals
| Return On Equity | -0.97 | |||
| Return On Asset | -0.52 | |||
| Current Valuation | (32.85 M) | |||
| Shares Outstanding | 27.58 M | |||
| Shares Owned By Insiders | 16.48 % | |||
| Shares Owned By Institutions | 68.38 % | |||
| Number Of Shares Shorted | 661.11 K | |||
| Price To Book | 0.65 X | |||
| EBITDA | (73.56 M) | |||
| Net Income | (72.26 M) | |||
| Cash And Equivalents | 90.73 M | |||
| Cash Per Share | 3.41 X | |||
| Total Debt | 277 K | |||
| Debt To Equity | 0 % | |||
| Current Ratio | 7.20 X | |||
| Book Value Per Share | 1.86 X | |||
| Cash Flow From Operations | (65.76 M) | |||
| Short Ratio | 1.90 X | |||
| Earnings Per Share | (2.07) X | |||
| Target Price | 1.58 | |||
| Number Of Employees | 63 | |||
| Beta | 0.27 | |||
| Market Capitalization | 44.01 M | |||
| Total Asset | 135.18 M | |||
| Retained Earnings | (165.69 M) | |||
| Working Capital | 111.66 M | |||
| Z Score | 92.82 | |||
| Net Asset | 135.18 M |
About Rain Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Rain Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Rain Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Rain Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Rain Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Rain Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Rain Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Rain Stock
| 0.65 | PPERY | Bank Mandiri Persero | PairCorr |
| 0.62 | PPERF | Bank Mandiri Persero | PairCorr |
| 0.7 | BKRKY | Bank Rakyat | PairCorr |
Moving against Rain Stock
| 0.81 | CSCO | Cisco Systems | PairCorr |
| 0.77 | BAC | Bank of America Fiscal Year End 10th of January 2025 | PairCorr |
| 0.66 | T | ATT Inc Fiscal Year End 22nd of January 2025 | PairCorr |
| 0.62 | AXP | American Express Fiscal Year End 24th of January 2025 | PairCorr |
| 0.6 | DIS | Walt Disney | PairCorr |
The ability to find closely correlated positions to Rain Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Rain Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Rain Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Rain Therapeutics to buy it.
The correlation of Rain Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Rain Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Rain Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Rain Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.
Other Consideration for investing in Rain Stock
If you are still planning to invest in Rain Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Rain Therapeutics' history and understand the potential risks before investing.
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance |